Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00481585 · ClinicalTrials.gov registry record
The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture
A clinical trial, sponsored by Hackensack Meridian Health.
- Terminated
- Registry status
- 13
- Enrollment target
NCT00481585: Clinical Trial study, sponsored by Hackensack Meridian Health.
NCT00481585 is a clinical trial that was terminated before completion, run by Hackensack Meridian Health. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00481585 was terminated before completion, sponsored by Hackensack Meridian Health.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The objective of the present study is to determine whether or not primary human mammary epithelial cells are competent for use in molecular studies of transepithelial electrophysiology focusing on the function of the tight junction protein claudin 3. Human breast Tissue will be removed from mastectomy specimens and used as a source to generate epithelial cells for study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2007-05 |
Why NCT00481585 stopped before completion
NCT00481585 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00481585 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00481585 about?
NCT00481585 is a clinical study titled "The Biology of Claudin 3 in Primary Human Mammary Epithelial Cell Culture". The objective of the present study is to determine whether or not primary human mammary epithelial cells are competent for use in molecular studies of transepithelial electrophysiology focusing on the function of the tight junction protein claudin 3. Human breast Tissue will be removed from mastect...
What is the current status of trial NCT00481585?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2007-05.
Who is sponsoring clinical trial NCT00481585?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia